Device type · CEC
Radioimmunoassay, Free Thyroxine
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
CEC
Clinical Chemistry
Device class
Class II
FDA decisions since 2015
7
510(k), De Novo and PMA
Adverse event reports
161
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Radioimmunoassay, Free Thyroxine
- Product code
- CEC
- Device class
- Class II
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1695
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for CEC
Latest FDA decisions
- Access Free T4510(k)
K240273 · Decided Mar 6, 2024 · 35 days after receipt
Device type: Radioimmunoassay, Free Thyroxine (CEC) · Laboratory Medicine & Pathology
- Elecsys FT4 IV510(k)
K220456 · Decided Apr 7, 2023 · 414 days after receipt
Device type: Radioimmunoassay, Free Thyroxine (CEC) · Laboratory Medicine & Pathology
- MAGLUMI 2000 FT4510(k)
Shenzhen New Industries Biomedical Engineering Co., Ltd.
K182423 · Decided Oct 4, 2018 · 28 days after receipt
Device type: Radioimmunoassay, Free Thyroxine (CEC) · Laboratory Medicine & Pathology
4 more FDA decisions with a free account
Reports received
161
Received Nov 1, 2025 to Nov 19, 2026. Includes 9 of another or unstated type.
Malfunction reports
152
94% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 6 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 14 | 0 | 0 | 0 |
| Mar 24 | 41 | 0 | 0 | 0 |
| Apr 24 | 31 | 1 | 0 | 0 |
| May 24 | 33 | 2 | 0 | 0 |
| Jun 24 | 24 | 0 | 0 | 0 |
| Jul 24 | 24 | 0 | 0 | 0 |
| Aug 24 | 23 | 0 | 0 | 0 |
| Sep 24 | 19 | 0 | 0 | 0 |
| Oct 24 | 33 | 0 | 0 | 0 |
| Nov 24 | 19 | 0 | 0 | 0 |
| Dec 24 | 12 | 0 | 0 | 0 |
| Jan 25 | 25 | 0 | 0 | 0 |
| Feb 25 | 10 | 0 | 0 | 0 |
| Mar 25 | 15 | 0 | 0 | 0 |
| Apr 25 | 27 | 0 | 0 | 0 |
| May 25 | 11 | 0 | 0 | 0 |
| Jun 25 | 17 | 0 | 0 | 0 |
| Jul 25 | 15 | 0 | 0 | 0 |
| Aug 25 | 18 | 0 | 0 | 0 |
| Sep 25 | 29 | 0 | 0 | 0 |
| Oct 25 | 18 | 0 | 0 | 0 |
| Nov 25 | 11 | 0 | 0 | 0 |
| Dec 25 | 17 | 0 | 0 | 0 |
| Jan 26 | 16 | 0 | 0 | 0 |
| Feb 26 | 8 | 0 | 0 | 0 |
| Mar 26 | 13 | 0 | 0 | 0 |
| Apr 26 | 21 | 0 | 0 | 0 |
| May 26 | 11 | 0 | 0 | 0 |
| Jun 26 | 16 | 0 | 0 | 0 |
| Jul 26 | 8 | 0 | 0 | 4 |
| Aug 26 | 12 | 0 | 0 | 0 |
| Sep 26 | 10 | 0 | 0 | 0 |
| Oct 26 | 9 | 0 | 0 | 5 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
- Abbott134
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results133
- Low Test Results23
- Incorrect, Inadequate or Imprecise Result or Readings7
6 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions160
- Hyperthyroidism1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2237-2020 · Started Apr 30, 2019 · Posted by FDA Jun 2, 2020
Reason given: The recalling firm characterized the potential interference effects of biotin (up to 1,200 ng/mL) on all biotin-mediated Access assays. The following six assays: Free T3-REF A13422, Total T3-REF 33830, Free T4-REF 33880, GI Mon-387687, Tg-REF 33860, and TgAbII-REF A32898 displayed significant interference (defined as...
Cause as FDA categorized it: Other
Abbott Ireland Diagnostics Division
Z-0665-2019 · Started Nov 21, 2018
Reason given: Abbott has become aware of a manufacturing issue that can result in damage to a bottle neck in some of the reagent cartridges found in the lots listed in Appendix A. If a bottle neck is damaged, it may cause a failure during the reagent loading process on the Alinity i instrument.
Cause as FDA categorized it: Nonconforming Material/Component
Z-2081-2018 · Started Mar 5, 2018
Reason given: Asfotase Alfa (Strensiq) interferes with certain Tosoh assays which potentially causes falsely increased or falsely decreased immunoassay test results, depending upon the assay.
Cause as FDA categorized it: Device Design
9 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.